The Expanding Continuum of Care in Metastatic Breast Cancer

Breast cancer is the most common cancer that affects women, with estimates that it will account for 30% of all new cancer diagnoses in women in 2020. As the most commonly overexpressed receptor in breast cancer, HER2 is amplified or overexpressed in about 15% of breast cancers, leading to dysregulated cell proliferation. This article explores the current breast cancer landscape, with a focus on emerging HER2-targeted therapies, and discusses the unmet needs within the treatment landscape.

Sara M. Tolaney, MD, MPH speaks to the testing and treatment advances for women with HER2-positive breast cancer.